Figure 2.

(a) Tumour growth rate in control‐ (Crl), vehicle‐ (Veh), propranolol (Prop)‐, and SR59230A (SR)‐ treated mice (n = 6). (b) Tumour growth rate in siRNA‐CTRL, siRNA‐β₂, and siRNA‐β₃ treated mice (n = 6). (c) MR images of mouse ventral section in control, vehicle‐, propranolol‐, and SR59230A‐treated mice (n = 6). (d) FACS analysis of AnnexinV positive cells in control, vehicle‐, propranolol‐, and SR59230A‐treated mice (n = 6). (e) FACS analysis of Fas marker expression in tumours of control, vehicle‐, propranolol ‐, and SR59230A‐treated mice (n = 6). (f) Representative fields of haematoxylin–eosin (H&E) staining at T14 in control, vehicle‐, propranolol‐, and SR59230A‐treated mice (n = 6). *P < 0.05 Prop‐ (or siRNA‐β₂) compared with Veh‐; ^# P < 0.05 SR‐ (or siRNA‐β₃) compared with Veh‐; ^$ P < 0.05 SR‐ (or siRNA‐β₃) compared with Prop‐ (or siRNA‐β₂)